UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

File	d by tl	he Registrant ⊠	Filed by a Party other than the Registrant \Box	
Che	ck the	appropriate box:		
	Preli	minary Proxy Statemen	t	
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))			
	Defii	Definitive Proxy Statement		
\times	Defi	Definitive Additional Materials		
□ Soliciting Material Pursuant to § 240.14a-12			to § 240.14a-12	
			CytomX Therapeutics, Inc.	
			(Name of Registrant as Specified In Its Charter)	
			(Name of Person(s) Filing Proxy Statement, if other than the Registrant)	
Pay	ment c	of Filing Fee (Check the	appropriate box):	
\times		ee required.		
			w per Exchange Act Rules 14a-6(i)(1) and 0-11.	
	(1)	litle of each class of s	securities to which transaction applies:	
	(2)	Aggregate number of	securities to which transaction applies:	
	(3)	-	underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing tate how it was determined):	
	(4)	Proposed maximum a	ggregate value of transaction:	
	(5)	Total fee paid:		
	Fee j	paid previously with pre	eliminary materials.	
			fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid	
	(1)	Amount Previously Pa	rious filing by registration statement number, or the Form or Schedule and the date of its filing.	
	` /			
	(2)	Form, Schedule or Re	gistration Statement No.:	
	(3)	Filing Party:		
	(4)	Date Filed:		

*** Exercise Your Right to Vote ***

Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on June 17, 2020.

CYTOMX THERAPEUTICS, INC.

Meeting Information

Meeting Type: Annual Meeting For holders as of: April 20, 2020

Date: June 17, 2020 Time: 1:00 PM PDT Location: Meeting live via the Internet-please visit

www.virtualshareholdermeeting.com/CTMX2020.

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

CYTOMX THERAFEUTICS, INC. 151 OYSTER POINT BLVD SUITE 400 SOUTH SAN FRANCISCO, CA 94080

D13043-P40181

- Before You Vote

How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:

NOTICE AND PROXY STATEMENT FORM 10-K

How to View Online:

How to Request and Receive a PAPER or E-MAIL Copy:

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

1) BY INTERNET: www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639

3) BY E-MAIL*: sendmaterial@proxyvote.com

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before June 3, 2020 to facilitate timely delivery.

— How To Vote —

Please Choose One of the Following Voting Methods

Vote By Internet:

Before The Meeting:

During The Meeting:

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

Voting Items

The Board of Directors recommends you vote FOR the following:

 To elect three directors with terms to expire at the 2023 Annual Meeting of Stockholders;

NomInees:

- 1a. Frederick W. Gluck
- 1b. Matthew P. Young
- 1c. Elaine V. Jones, Ph.D.

The Board of Directors recommends you vote FOR proposals 2, 3 and 4:

- To ratify the selection of Ernst & Young LLP as our Independent registered public accounting firm for the fiscal year ending December 31, 2020;
- To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to Increase the number of authorized shares of common stock from 75,000,000 to 150,000,000;
- To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; and

NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Annual Meeting.